Hui Jing

List of Publications by Year
in descending order

27 papers	1,922 citations	279798 23 h-index	501196 28 g-index
33 all docs	33 docs citations	33 times ranked	2653 citing authors

#	Article	IF	Citations
1	The Substrate Specificity of Sirtuins. Annual Review of Biochemistry, 2016, 85, 405-429.	11.1	208
2	Sirtuins in Epigenetic Regulation. Chemical Reviews, 2015, 115, 2350-2375.	47.7	205
3	A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer Cell, 2016, 29, 297-310.	16.8	183
4	Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. Cell Research, 2020, 30, 833-853.	12.0	149
5	Sirtuin inhibitors as anticancer agents. Future Medicinal Chemistry, 2014, 6, 945-966.	2.3	148
6	Efficient Demyristoylase Activity of SIRT2 Revealed by Kinetic and Structural Studies. Scientific Reports, 2015, 5, 8529.	3.3	143
7	Abrogation of Akt signaling by Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells. Cancer Letters, 2010, 294, 167-177.	7.2	80
8	Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer Cell, 2019, 35, 916-931.e9.	16.8	70
9	SIRT2 and lysine fatty acylation regulate the transforming activity of K-Ras4a. ELife, 2017, 6, .	6.0	70
10	Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. Blood, 2018, 131, 2698-2711.	1.4	66
11	SIRT6 regulates Ras-related protein R-Ras2 by lysine defatty-acylation. ELife, 2017, 6, .	6.0	62
12	Selective blockade of the lyso-PS lipase ABHD12 stimulates immune responses in vivo. Nature Chemical Biology, 2018, 14, 1099-1108.	8.0	55
13	Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acidâ€“Induced Differentiation by Modifying the RARÎ±/STAT1 Axis. Molecular Cancer Therapeutics, 2013, 12, 195-206.	4.1	38
14	Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activityâ€Dependent Inhibition, and Onâ€Target Anticancer Activities. ChemMedChem, 2018, 13, 1890-1894.	3.2	38
15	Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Reports, 2021, 37, 109957.	6.4	38
16	A Smallâ€Molecule SIRT2 Inhibitor That Promotes Kâ€Ras4a Lysine Fattyâ€Acylation. ChemMedChem, 2019, 14, 744-748.	3.2	36
17	MEK/ERK Dependent Activation of STAT1 Mediates Dasatinib-Induced Differentiation of Acute Myeloid Leukemia. PLoS ONE, 2013, 8, e66915.	2.5	35
18	Simultaneous Inhibition of SIRT2 Deacetylase and Defatty-Acylase Activities via a PROTAC Strategy. ACS Medicinal Chemistry Letters, 2020, 11, 2305-2311.	2.8	29

#	Article	IF	Citations
19	Discovery and Optimization of Selective and in Vivo Active Inhibitors of the Lysophosphatidylserine Lipase Î±/Î²-Hydrolase Domain-Containing 12 (ABHD12). Journal of Medicinal Chemistry, 2019, 62, 1643-1656.	6.4	27
20	Comparative Nucleotide-Dependent Interactome Analysis Reveals Shared and Differential Properties of KRas4a and KRas4b. ACS Central Science, 2018, 4, 71-80.	11.3	25
21	SIRT2 and Lysine Fatty Acylation Regulate the Activity of RalB and Cell Migration. ACS Chemical Biology, 2019, 14, 2014-2023.	3.4	25
22	Blockade of the Lysophosphatidylserine Lipase ABHD12 Potentiates Ferroptosis in Cancer Cells. ACS Chemical Biology, 2020, 15, 871-877.	3.4	25
23	The ubiquitin-proteasome pathway plays essential roles in ATRA-induced leukemia cells G₀/G₁phase arrest and transition into granulocytic differentiation. Cancer Biology and Therapy, 2010, 10, 1157-1167.	3.4	23
24	The Spastic Paraplegia-Associated Phospholipase DDHD1 Is a Primary Brain Phosphatidylinositol Lipase. Biochemistry, 2018, 57, 5759-5767.	2.5	22
25	Phospholipase CÎ³2 regulates endocannabinoid and eicosanoid networks in innate immune cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	15
26	Involvement of mitogenâ€activated protein kinase in signal transducer and activator of transcriptionâ€1 mediated differentiation induced by bortezomib in acute myeloid leukemia cells. Molecular Carcinogenesis, 2013, 52, 18-28.	2.7	8
27	Lessons learned from a SIRT2-selective inhibitor. Oncotarget, 2016, 7, 22971-22972.	1.8	2